Microneedling with or without PRP for macular amyloidosis
Part of Skin clinical trials.
This trial compares two treatments for macular amyloidosis, a skin condition causing brown patches. It tests if microneedling alone or microneedling combined with platelet-rich plasma (PRP) works better. Each side of your face gets a different treatment, and the results are compared.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with macular amyloidosis (confirmed by a skin exam and biopsy).
- You have not used any skin creams or ointments for this condition in the past 4 weeks.
- You have not had any procedures like chemical peels or laser in the past month.
- You have not taken any oral medication for macular amyloidosis in the past 12 weeks.
- You do not have other skin conditions (like psoriasis or eczema), immune problems, bleeding disorders, or a history of keloids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two treatments made from your own blood—platelet-rich fibrin (PRF) and platelet-rich plasma (PRP)—when used with microneedling to reduce sun damage and aging on the face. The goal is to see which one works better for improving skin texture and tone.
This trial compares two treatments for acne scars: microneedling combined with platelet-rich plasma (PRP), versus microneedling combined with insulin. The goal is to see which works better for improving scar appearance.
This trial tests if microneedling with either lactic acid, vitamin D3, or a steroid cream helps regrow hair in people with patchy alopecia areata (small bald spots).
This study compares two face treatments for rejuvenation: microneedling with radiofrequency alone, or combined with a topical collagen-stimulating material (poly-L-lactic acid). It aims to see which better restores facial fullness and skin health.
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
Hear when a new Macular Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.